Kang Y K - Asan Medical Center, University of Ulsan

基本信息

浏览量：67

职业迁徙

个人简介

暂无内容

研究兴趣

论文共 43 篇作者统计合作学者相似作者

按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选

Nivolumab plus ipilimumab combination therapy in patients with advanced hepatocellular carcinoma previously treated with sorafenib: 5-year results from CheckMate 040

I. Melero, T. Yau,Y.-K. Kang,T.-Y. Kim, A. Santoro, B. Sangro, M. Kudo, M.-M. Hou, A. Matilla, F. Tovoli, J. Knox, A.R. He,

Annals of Oncology (2024)

引用0浏览0引用

1526P Phase Ib results of bemarituzumab (BEMA)+mfolfox6+nivolumab (NIVO) for advanced gastric/gastroesophageal junction cancer (G/GEJC): Fortitude-102 part 1

Z.A. Wainberg, K. Yamaguchi,J.A. Ajani, J. Chao, M. Moehler,Y-K. Kang,E. Van Cutsem, P. Yen, Y. Motii,D. Zhou, T. Murias Dos Santos,K. Shitara

Annals of Oncology (2023): S859-S859

引用0浏览0引用

Safety and efficacy of tusamitamab ravtansine in patients with colorectal or gastric cancer expressing carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5)

A. Italiano, A. Gazzah,J. Tabernero,Y-K. Kang,E. Calvo,M. Provencio Pulla,Y-J. Bang, F. Barlesi,P. L. Bedard, J. O. Park,J-S. Kim, M. Chadjaa,

ANNALS OF ONCOLOGY（2022）

引用0浏览0引用

Safety and efficacy of HER2 blockade by trastuzumab-based chemotherapy-containing combination strategies in HER2+ gastroesophageal adenocarcinoma

D V T Catenacci,H C Chung, L Shen, M Moehler, H H Yoon,M K Rosales,Y-K Kang

ESMO Open（2022）

引用4浏览0WOS引用

Safety, pharmacokinetics, and antitumor activity of the anti-CEACAM5-DM4 antibody–drug conjugate tusamitamab ravtansine (SAR408701) in patients with advanced solid tumors: first-in-human dose-escalation study

A Gazzah, P L Bedard, C Hierro,Y-K Kang,A Abdul Razak, M-H Ryu, B Demers, N Fagniez, C Henry, M Hospitel,J-C Soria,J Tabernero

Annals of Oncology（2022）

引用30浏览0WOS引用

Phase Ib/Ii Open-Label, Randomised Evaluation Of Second-Line Atezolizumab (Atezo) Plus Linagliptin (Lina) Vs Ramucirumab (Ram) Plus Paclitaxel (Pac) In Morpheus-Gastric Cancer

J. Lee,J. A. Ajani, H. C. Chung,Y-K. Kang, S. Iqbal,S. Allen, N. Al-Sakaff, J. Decalf, S. Li, J. Pintoffl, P. Sayyed,Y-J. Bang

ANNALS OF ONCOLOGY（2021）

引用1浏览0引用

Long-Term Efficacy, Tolerability And Overall Survival In Patients (Pts) With Unresectable Or Metastatic (U/M) Pdgfra D842v-Mutant Gastrointestinal Stromal Tumour (Gist) Treated With Avapritinib: Navigator Phase I Trial Update

Y-K. Kang,R. L. Jones,M. Von Mehren,C. Serrano,S. George,M. C. Heinrich,P. Schoffski, O. Mir,P. A. Cassier,F. Eskens, P. Rutkowski, W. D. Tap,

Annals of Oncology（2020）

引用7浏览0引用

1635P Clinical and pathologic prognostic factors for residual lesion surgery following disease control with standard dose imatinib (IM) in patients (pts) with advanced gastrointestinal stromal tumor (GIST)

H. Cho, M.H. Ryu,S.M. Lee, Y. Park, Y.S. Park,H. Chae,K-H. Kim,C.W. Kim,B.S. Kim,M-W. Yoo,Y-K. Kang

Annals of Oncology（2020）

引用0浏览0引用

A phase II, randomised study of mFOLFOX6 with or without the Akt inhibitor ipatasertib in patients with locally advanced or metastatic gastric or gastroesophageal junction cancer

Y-J Bang,Y-K Kang,M Ng,H C Chung,Z A Wainberg, S Gendreau,W Y Chan,N Xu, D Maslyar,R Meng,I Chau,J A Ajani

European Journal of Cancer（2019）

引用32浏览0WOS引用

Phase Iii Randomized Study Of Neoadjuvant Chemotherapy (Ct) With Docetaxel(D), Oxaliplatin(O) And S-1(S) (Dos) Followed By Surgery And Adjuvant S-1, Vs Surgery And Adjuvant S-1, For Resectable Advanced Gastric Cancer (Gc) (Prodigy)

Y-K. Kang,J. H. Yook,Y-K. Park,Y-W. Kim,J. Kim,M-H. Ryu,S. Y. Rha,I-J. Chung,I-H. Kim,S. C. Oh,C-H. Yoo,J-H. Choi,

ANNALS OF ONCOLOGY（2019）

引用26浏览0引用

加载更多

作者统计

合作学者

合作机构

D-Core

合作者
学生
导师

暂无相似学者，你可以通过学者研究领域进行搜索筛选

数据免责声明

页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果，我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问，可以通过电子邮件方式联系我们：report@aminer.cn